Result for
Topic: Testing and Treatment
January 7, 2021
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
In a randomized, double-blind, placebo-controlled trial of non-hospitalized adults aged ≥75 years (n=160) with mild COVID-19, patients who received convalescent plasma within 72 hours after onset of symptoms were 48% less likely to develop severe respiratory disease than patients receiving placebo (RR = 0.52, 95% CI: 0.29-0.94). Risk of severe disease was 60% lower (RR…
January 5, 2021
Performance of At-Home Self-Collected Saliva and Nasal-Oropharyngeal Swabs in the Surveillance of COVID-19
A study assessing the performance of at-home self-collected saliva and nasal-oropharyngeal (NOP) swabs for SARS-CoV-2 testing (RT-PCR) among patients who met the criteria for suspected COVID-19 identified 70 out of 201 patients with positive samples from saliva, NOP, or both swabs. 37/70 (53%) were positive in both swabs, 18/70 (26%) were positive in saliva swabs…
January 4, 2021
Longitudinal Testing for Respiratory and Gastrointestinal Shedding of SARS-CoV-2 in Day Care Centres in Hesse, Germany
A longitudinal study of children (n=859, age 3 months – 8 years) and staff (n=376) from daycare centers in Germany conducted from June-September 2020 found that detection of either respiratory or gastrointestinal shedding of SARS-CoV-2 RNA was rare in the context of limited community activity and with facility-based infection prevention measures. Of 7,366 buccal mucosa…
Performance of an Antigen-Based Test for Asymptomatic and Symptomatic SARS-CoV-2 Testing at Two University Campuses — Wisconsin, September–October 2020
Use of SARS-CoV-2 antigen testing on two university campuses had a positive predictive value of 33% and a negative predictive value of 99%. Compared to RT-PCR testing, the Sofia antigen test had a sensitivity of 80.0% and specificity of 98.9% among symptomatic people. Accuracy was lower (sensitivity 41.2% and specificity 98.4%) when used for screening…
December 30, 2020
Field Performance and Public Health Response Using the BinaxNOW Rapid SARS-CoV-2 Antigen Detection Assay during Community-Based Testing
Among 3,302 persons tested for SARS-CoV-2 by BinaxNOW Rapid SARS-CoV-2 antigen detection assay in a community setting with 7.2% prevalence, rapid assay sensitivity was 100%, 98.5%, and 89% using RT-PCR Ct thresholds of 30, 35 and none, respectively. The assay maintained high sensitivity performance across ages and those with and without symptoms. Assay specificity was…
December 28, 2020
Patterns of SARS-CoV-2 testing preferences in a national cohort in the United States
[pre-print; not peer-reviewed] Based on results from a discrete choice experiment (n=4,793), the uptake for testing for SARS-CoV-2 was predicted to increase by 82% to 98% if less invasive testing (saliva specimen type), dual testing (both viral and antibody tests), and at home testing scenarios were offered in addition to standard testing scenarios. Romo et…
December 23, 2020
Multiplex Assays for the Identification of Serological Signatures of SARS-CoV-2 Infection: An Antibody-Based Diagnostic and Machine Learning Study
Testing for multiple biomarkers, as opposed to testing for a single antibody, increased the sensitivity of correctly identifying past SARS-CoV-2 infection. A multiplex serological assay was used to measure IgG and IgM antibody responses to seven SARS-CoV-2-specific antigens, two seasonal coronavirus antigens, and three non-coronavirus antigens. Antibodies were measured in serum samples collected up to…
ACTIV-3/TICO LY-CoV555 Study Group. (Dec 22, 2020). A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
A randomized clinical trial among patients hospitalized with COVID-19 that aimed to assess the effect of LY-CoV555, a neutralizing monoclonal antibody, was halted due to futility after 314 patients had undergone infusion with either the antibody or a placebo. Patients who received the antibody infusion did not have better clinical outcomes at day five than…
December 18, 2020
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
Tocilizumab reduced the rate of mechanical ventilation, but did not prevent deaths among hospitalized COVID-19 patients. In a randomized trial of patients hospitalized with COVID-19 pneumonia who were not receiving mechanical ventilation, tocilizumab reduced the likelihood of progression to the composite outcome of mechanical ventilation or death, but did not improve survival. The cumulative percentage…
December 17, 2020
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
An interim analysis of the ongoing randomized placebo-controlled phase 1-3 trial of the antibody cocktail REGN-COV2 among non-hospitalized patients with COVID-19 (n=228) found a larger reduction in SARS-CoV-2 viral load among patients in the treatment group vs. the placebo group, with a mean difference of -0.41 log10 copies per milliliter (95% CI, −0.71 to −0.10)….
Previous page Next page